Skip to content

A nationwide multicenter real-world clinical study on injectable cetriptyline for hematological diseases

A nationwide multicenter real-world clinical study on injectable cetriptyline for hematological diseases

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500106789
Enrollment
Unknown
Registered
2025-07-30
Start date
2025-07-30
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diseases of blood system

Interventions

Observation group (Treatment with Cetriptyline Injection):None

Sponsors

Guangdong Provincial Hosipital of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. The patient signs an informed consent form, voluntarily joins this study, and has the willingness and ability to cooperate with data collection in this study; 2. Clinical diagnosis are hematological disorders; 3. Intending to receive or have received treatment with injectable cetriptyline (whether to prescribe injectable cetriptyline is determined by the supervising physician and is not affected by this study).

Exclusion criteria

Exclusion criteria: 1. The patient is undergoing clinical intervention research; 2. Unable to understand the nature of the research or without obtaining informed consent; 3. Researchers determine other situations that are not suitable for inclusion in the study.

Design outcomes

Primary

MeasureTime frame
adverse events;

Secondary

MeasureTime frame
overall survival;progression-free survival;recurrence rate;

Countries

China

Contacts

Public ContactYuanbin Wu

Guangdong Provincial Hosipital of Chinese Medicine

wuyuanbin1977@sohu.com+86 137 1145 4979

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026